**Biomedical Informatics Grand Rounds**

**Patricia Thompson, MD, PhD**  
Professor of Pathology  
Interim Program Leader for Imaging, Bioinformatics and Engineering Science  
Deputy Director Stony Brook Cancer Center

Sulindac, a non-steroidal anti-inflammatory drug, reduces breast density and alters collagen alignment in breast tissue.

**Wednesday, September 5, 2018  3pm—4pm**  
Atkins Center – HSC Level 4 (Radiology)

**Abstract:**

Non-steroidal anti-inflammatory agents like aspirin and the non-selective cyclooxygenase inhibitor sulindac have been shown in preclinical experimental models to prevent the development of epithelial tumorigenesis. Results of an interim analysis of a Phase II biomarker clinical study of sulindac 150 mg twice daily for 12 months compared to no treatment control on change in breast density, an intermediate biomarker of breast cancer risk, will be presented. Results for effects of sulindac on tissue collagen alignment and collagen fiber type will be discussed along with plans for novel microscopy work of collagen in breast tissue as a biomarker of risk.

**Learning Objectives:**

1) Describe the effects of non-steroidal anti-inflammatory agents as cancer chemoprevention agents for breast and other cancers.

2) Explain the relationship between breast density and breast cancer risk.

3) Relate the effects of cancer prevention agents on breast density to their relationship to breast cancer risk.

4) Discuss the role of the tissue microenvironment as a drug target for cancer prevention.

**CME CREDIT AVAILABLE**

Questions? Please call the Biomedical Informatics Department at 631-638-2590.